WO2000010555A1 - Methode de prevention de la tuberculose chez le jeune betail - Google Patents

Methode de prevention de la tuberculose chez le jeune betail Download PDF

Info

Publication number
WO2000010555A1
WO2000010555A1 PCT/RU1999/000257 RU9900257W WO0010555A1 WO 2000010555 A1 WO2000010555 A1 WO 2000010555A1 RU 9900257 W RU9900257 W RU 9900257W WO 0010555 A1 WO0010555 A1 WO 0010555A1
Authority
WO
WIPO (PCT)
Prior art keywords
tuberculin
tuberculosis
immunomodulator
animals
disease
Prior art date
Application number
PCT/RU1999/000257
Other languages
English (en)
Russian (ru)
Inventor
Vladislav Nikolaevich Laskavy
Erika Davydovna Lakman
Original Assignee
Vladislav Nikolaevich Laskavy
Erika Davydovna Lakman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vladislav Nikolaevich Laskavy, Erika Davydovna Lakman filed Critical Vladislav Nikolaevich Laskavy
Priority to AU53107/99A priority Critical patent/AU5310799A/en
Priority to EA200000241A priority patent/EA002195B1/ru
Publication of WO2000010555A1 publication Critical patent/WO2000010555A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Definitions

  • the invention is subject to veterinary medicine and may be used for the treatment of tuberculosis - an infectious disease common for humans and livelihoods.
  • a method of treating a young child’s large catastrophe with the use of a lively vaccine has been known to have caused an injury.
  • the method includes the intrinsic administration of 0.3 ml of a vaccine containing 1 mg of live BCG vaccines to calves of 10-20 days old, which accounts for 8-10 cm of the patient. After 14-16 months after immunization, animals are examined by the internal administration of tuberculin; Reacting surrender to slaughter, others, in the future, are investigated in order, inadequate sanitary (SP 3.1.093-96) and in veterinary (ZP 13.3.1325) didn’t take care of common to people and livelihoods. ” The sanitary and veterinary ward was corrected by the State Sanitary and Epidemiological Supervision and the General Administration of Russia.
  • BCG with immunomodulators as a rule, use a highly popular ⁇ from other ( ⁇ ).
  • the main task of the invention was to ensure the effective treatment of high-speed discharges to a significant rate of overload.
  • P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ u ⁇ em vnu ⁇ imyshechny ⁇ ine ⁇ tsy ⁇ - ⁇ ila ⁇ iches ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a and immun ⁇ m ⁇ dulya ⁇ a in ⁇ aches ⁇ ve ⁇ ila ⁇ i- ches ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a is ⁇ lzuyu ⁇ ⁇ ube ⁇ ulin ( ⁇ ube ⁇ ul ⁇ ein), and in ⁇ aches ⁇ ve immun ⁇ m ⁇ dulya ⁇ a - ⁇ e ⁇ a ⁇ a ⁇ , s ⁇ de ⁇ zhaschy (wt.%): ⁇ maldegid - 0.07-0.1 ; Chloride nation - 0.9-0.95; distilled water - the rest, and at the same time, first introduced tuberculin of a young, young, after 3-4 ml a day, after a little 40-40 minutes, after a little 40-40 minutes
  • ⁇ ⁇ ezul ⁇ a ⁇ e is ⁇ lz ⁇ vaniya in ⁇ aches ⁇ ve ⁇ ila ⁇ iches ⁇ g ⁇ s ⁇ eds ⁇ va - ⁇ ube ⁇ ulina, and ⁇ aches ⁇ ve immun ⁇ m ⁇ dulya ⁇ a - ⁇ e ⁇ a ⁇ a ⁇ a on ⁇ sn ⁇ ve ⁇ - maldegida udae ⁇ sya ⁇ susches ⁇ vi ⁇ e ⁇ e ⁇ ivnuyu ⁇ ila ⁇ i ⁇ u ⁇ ube ⁇ uleza in znachi ⁇ eln ⁇ ⁇ ie s ⁇ i.
  • BCG live tuberculosis cell carcinoma
  • tuberculin is associated with a specific desensitization with simultaneous stimulation of the synthesis of paranulia.
  • a parenterally administered tuberculin causes an immunocompromised, similar BCG vaccine, but in a more rapid way and without sensitization of the body.
  • the use of a consumer-friendly product in the quality of the product generates shipping charges and for simultaneous use of an immune device that is immune to 105.
  • tuberculin is adsorbed on battery cells, and is administered by the preparation on base of maldehyde, as a result of which is neglected.
  • tuberculin The dose of tuberculin is conveniently experimentally administered. It has been established that the administration of tuberculin in a dose of less than 3 ml does not lead to the solution of the fixed task, but it is the creation of a long-term intense immune system. The introduction of tuberculin more than 4 ml is inexpedient with economic
  • an immunomodulator of 4–6 ml is also conveniently experimental.
  • An interval of 30–40 minutes between injections corresponds to the largest area of injection at the place of injection, and that is caused by an increased phase of the external disease.
  • tuberculin tuberculosis
  • Immunomodulant provides a colorless, potent liquid with a mild form of starch.
  • the benefit of the method is that, if the patient is ill-disposed of, he or she will receive the health of the body from his perception to replace bad welfare.
  • the use of the method removes the problem of further diagnosis of the disease in healthy animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention relève de la médecine vétérinaire et peut servir à la prévention de la tuberculose, maladie contagieuse commune aux humains et aux animaux. La méthode de prévention de la tuberculose chez le jeune bétail consiste à faire des injections intramusculaires d'une formulation préventive et d'un immunomodulateur. La formulation préventive consiste en de la tuberculine (tuberculine PPD), l'immunomodulateur se présentant comme une formulation contenant 0,07-0,1 % en poids de formaldéhyde et 0,9-0,95 % en poids de chlorure de sodium, le reste étant constitué d'eau distillée. On injecte d'abord une dose unique de tuberculine à des jeunes animaux à l'âge où ils absorbent le colostrum, ladite dose étant de 3-4 ml par tête de bétail, et 30-40 minutes après on injecte l'immunomodulateur, chaque dose comportant 4-6 ml par tête. La méthode proposée de prévention de la tuberculose chez le jeune bétail permet de conférer aux veaux une résistance élevée à l'agent pathogène de la tuberculose, et ce dans des fermes désavantagées de façon permanente tout comme dans des foyers de maladie aiguë. La mise en oeuvre de cette méthode permet de créer des troupeaux de génisses saines à partir des animaux d'une ferme donnée afin de remplacer les animaux à problèmes. En outre, l'utilisation de cette méthode résout le problème de diagnostic ultérieur de la tuberculose chez les animaux immunisés.
PCT/RU1999/000257 1998-08-19 1999-07-27 Methode de prevention de la tuberculose chez le jeune betail WO2000010555A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU53107/99A AU5310799A (en) 1998-08-19 1999-07-27 Method of preventing tuberculosis in young cattle
EA200000241A EA002195B1 (ru) 1998-08-19 1999-07-27 Способ профилактики туберкулеза молодняка крупного рогатого скота

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU98115741A RU2146533C1 (ru) 1998-08-19 1998-08-19 Способ профилактики туберкулеза молодняка крупного рогатого скота
RU98115741 1998-08-19

Publications (1)

Publication Number Publication Date
WO2000010555A1 true WO2000010555A1 (fr) 2000-03-02

Family

ID=20209703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1999/000257 WO2000010555A1 (fr) 1998-08-19 1999-07-27 Methode de prevention de la tuberculose chez le jeune betail

Country Status (4)

Country Link
AU (1) AU5310799A (fr)
EA (1) EA002195B1 (fr)
RU (1) RU2146533C1 (fr)
WO (1) WO2000010555A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172195A1 (fr) * 2007-07-04 2010-04-07 Vladislav Nikolaevich Laskavy Agent à effet hypocholestérolémiant

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724144A (en) * 1984-02-17 1988-02-09 University College London Immuno-therapeutic composition of killed cells from mycobacterium vaccae
GB2236480A (en) * 1989-08-09 1991-04-10 Nat Inst Immunology Tuberculosis vaccine
RU2077882C1 (ru) * 1995-11-21 1997-04-27 Владислав Николаевич Ласкавый Иммуномодулирующее средство

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724144A (en) * 1984-02-17 1988-02-09 University College London Immuno-therapeutic composition of killed cells from mycobacterium vaccae
GB2236480A (en) * 1989-08-09 1991-04-10 Nat Inst Immunology Tuberculosis vaccine
RU2077882C1 (ru) * 1995-11-21 1997-04-27 Владислав Николаевич Ласкавый Иммуномодулирующее средство

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Veterinarnaya mokrobiologiya, under editorship E.V. KOZLOVSKOGO et al., Moscow, (kolos), 1982, pages 248, 252. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172195A1 (fr) * 2007-07-04 2010-04-07 Vladislav Nikolaevich Laskavy Agent à effet hypocholestérolémiant
EP2172195A4 (fr) * 2007-07-04 2010-09-01 Vladislav Nikolaevich Laskavy Agent à effet hypocholestérolémiant
CN102727472A (zh) * 2007-07-04 2012-10-17 弗拉季斯拉夫·尼古拉耶维奇·拉斯卡维 一种制剂在制备调节胆固醇药物中的应用

Also Published As

Publication number Publication date
RU2146533C1 (ru) 2000-03-20
EA002195B1 (ru) 2002-02-28
AU5310799A (en) 2000-03-14
EA200000241A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
James et al. The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis.
Cook et al. A live attenuated turkey rhinotracheitis virus vaccine. 2. The use of the attenuated strain as an experimental vaccine
PT1322330E (pt) Modulação de resposta alérgica
Hirsch et al. Effects of anti-thymocyte serum on Rauscher virus infection of mice
Neitz, WO and Alexander The immunisation of calves against heartwater
Johnson Derriengue: vampire bat rabies in Mexico
Brown et al. Immunogenicity and efficacy of two rabies vaccines in wild-caught, captive raccoons
Harte et al. Failure of malaria vaccination in mice born to immune mothers.
Bano et al. A review of rabies disease, its transmission and treatment
Plotkin et al. Prevention of rabies in man
Morrill et al. Epidemiology and pathogenesis of Rift Valley fever and other phleboviruses
WO2000010555A1 (fr) Methode de prevention de la tuberculose chez le jeune betail
Wilson et al. Mucosal vaccine development for veterinary and aquatic diseases
Courter Bat rabies
Yamamoto et al. Existence of cytotoxic acitivity against BLV-transformed cells in lymphocytes from normal cattle and sheep
RU2181283C2 (ru) Способ профилактики репродуктивно-респираторного синдрома свиней
Elsdon-Dew Taeniasis in the Bantu
Nieves et al. Subcutaneous rabies vaccination of pigtail macaques
Hilke Investigations on the vaccination against the Bluetongue Virus serotypes 4 and 8 in sheep
RU2131218C1 (ru) Способ диагностики туберкулеза крупного рогатого скота
Ferreira Development of an experimental vaccine against neosporosis in cattle
Moges et al. Veterinary Vaccines: Unlocking the Power of Immunization for Livestock Health—A Review
Habel Prevention of rabies in man
Hoptman Brucellosis in the USSR: A Review of the Literature
Trisunuwati et al. Animal Health and Disease Prevention

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 200000241

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase